Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation - PubMed
4 days ago
- #Anaphylaxis
- #KIT Tyrosine Kinase Inhibitors
- #Systemic Mastocytosis
- Systemic mastocytosis (SM) is a hematologic disorder characterized by uncontrolled expansion and accumulation of mast cells (MC) in various organs.
- Most cases involve the KIT mutation D816V, leading to symptoms from organ infiltration and mediator release, sometimes causing severe or life-threatening anaphylaxis.
- Management includes avoidance of triggers, histamine receptor blockers, and drugs targeting MC activation or expansion.
- Novel KIT D816V-targeting drugs can reduce MC burden and improve quality of life by targeting signaling processes in neoplastic MC.
- The article reviews the role of MC and basophils in anaphylactic reactions in SM patients, including genetic variables, co-morbidities, and factors counteracting MC activation.